Goldman Sachs cuts Pfizer stock price target to $32 from $33
The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...
DZ BANK AG Sticks to Its Buy Rating for Pfizer (PFE)
In a report released today, Elmar Kraus from DZ BANK AG maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares opened ...
Pfizer (NYSE:PFE) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Here’s Why Pfizer Inc. (PFE) Is Among the Best Dividend Stocks Under $30
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Pfizer (NYSE:PFE) Price Target Cut to $29.00 by Analysts at Citigroup
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...
The Pharma Letter1d
Pfizer beats sales and earnings forecast in 4th-qtr
US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...
Pfizer beats Q4, FY '24 earnings estimates, stock flat in premarket trading
Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...
Hosted on MSN14h
Amgen, Merck and Pfizer Release Latest Quarterly Earnings, Share 2025 Plans
Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...